RLAY Relay Therapeutics

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 22, 2024.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or .

Contact:

Megan Goulart

617-545-5526

Media:

Dan Budwick

1AB

973-271-6085



EN
15/02/2024

Underlying

RLAYRelay Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relay Therapeutics

 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics to Announce First Quarter 2024 Financial Results an...

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024 CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Thursday, May 2, 2024. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming th...

April 25, 2024 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics to Participate in Upcoming Investor Conferences

Relay Therapeutics to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024 at 1:00 p.m. ETThe Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024 at 11:30 a.m. ETBofA Securities Health Care Conference 2024 on T...

April 11, 2024 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics to Participate in Three Upcoming Investor Conferenc...

Relay Therapeutics to Participate in Three Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: TD Cowen’s 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 a.m. ETLeerink Partners’ 2024 Global Biopharma Conference on Monday, March 11, 2024 at 10:40 a.m. ETBarclays 26th Annual Global Health...

February 26, 2024 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial...

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-mutated HR+/HER2- metastatic breast cancer Approximately $750 million in cash, cash equivalents and investments at end of Q4 2023, expected to fund operations into second half of 2026 CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a ...

February 22, 2024 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Finan...

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024 CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 22, 2024. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage p...

February 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch